Company Profile For Biodel Inc.

Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut. The Company is focused on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis. The Company develops product candidates by applying its formulation technologies to existing drugs in order to improve their therapeutic results. The Company’s initial development efforts are focused on peptide hormones. The Company’s advanced product candidate, VIAject, has been studied in two pivotal Phase III clinical trials for the treatment of patients with Type 1 and Type 2 diabetes. Earlier stage product candidates include VIAtab, a sublingual tablet formulation of insulin and two preclinical product candidates for the treatment of osteoporosis. The Company has developed all of its product candidates utilizing its VIAdel technology that allows the Company to study the interaction between peptide hormones and small molecules.

BRIEF: For the nine months 30 June 2009, Biodel Inc. reported no revenues. Net loss applicable to Common rose 7% to $32.8M. Revenues reflect the Company is still being in the development stages of its operations. Higher loss reflects an increase in research & development expenses and a decrease in interest & other income. The Company is engaged in the development & commercialization of innovative treatments for endocrine disorders.